MedWaves reports on its ongoing studies using the AveCure microwave coagulation-ablation system

MedWaves, Inc. announces ongoing investigational studies to determine the effectiveness of its microwave ablation system for treating soft tissue lesions, such as tumors, in liver and lung. The studies using MedWaves' AveCure(TM) microwave coagulation-ablation system, which includes a generator and probe/antenna (FDA 510(k) cleared and CE Mark certified), are showing promising results.

The AveCure(TM) system, which includes a microwave generator and sterile single-patient-use probes, enables the surgeons and interventional radiologists to safely treat soft tissue problems, such as tumors in the liver and lung, using thermal coagulation-ablation. AveCure(TM) system uses temperature and power feedback from the antenna and nearby tissue to intelligently control microwave power to the ablation zone. The changes in temperature and power absorption are indicative of thermal tissue destruction brought on by microwave energy absorbed in the ablation zone. By utilizing and displaying dynamic changes in temperature and power, MedWaves' AveCure(TM) system safely and efficiently ablates small or large zones using far less power than other ablation systems in the market. The same feedbacks are available for the user to manage the ablation process with confidence. Therefore, MedWaves' is inherently safer, does not require irrigation cooling, and less likely to cause collateral damage as with other systems currently in the market.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
UT Health San Antonio researcher awarded $2.53 million NIH grant to study alcohol-assisted liver disease